Tixagevimab and Cilgavimab

Kathryn Dzintars, Pharm.D., BCPS
Tixagevimab and Cilgavimab is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.

AND

  • Have moderate to severe immune-compromised status due to a medical condition or immunosuppressive medications/treatment and may not mount an adequate immune response from COVID-19 vaccination

OR

  • For whom vaccination with any available COVID-19 vaccine, according to the approved/authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or vaccine component

Tixagevimab/cilgavimab is NOT indicated for:

  • The treatment of COVID-19 disease
  • Post-exposure (PEP) of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2

PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.

AND

  • Have moderate to severe immune-compromised status due to a medical condition or immunosuppressive medications/treatment and may not mount an adequate immune response from COVID-19 vaccination

OR

  • For whom vaccination with any available COVID-19 vaccine, according to the approved/authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or vaccine component

Tixagevimab/cilgavimab is NOT indicated for:

  • The treatment of COVID-19 disease
  • Post-exposure (PEP) of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2

PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 17, 2022